IQVIA Holdings, Inc.

Valuation Analysis

About the Company

IQVIA Holdings, Inc. en bref

IQVIA Holdings, Inc. (IQV) is currently trading at 146,26 € with a market capitalization of 24,4 Md €. The trailing P/E ratio stands at 20.87x, with a forward P/E of 11.82x. The 52-week range spans from 133,39 € to 215,37 €; the current price is 32.1% below the yearly high. Year-over-year revenue growth stands at +8.4%. The net profit margin stands at 8.33%.

💰 Dividende

IQVIA Holdings, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

19 analystes évaluent IQVIA Holdings, Inc. (IQV) au consensus : Achat Fort. L'objectif de cours moyen est de 197,85 €, soit un potentiel de +35.27% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 169,99 € à 250,20 €.

IQVIA Holdings, Inc. : la thèse d'investissement en détail

IQVIA Holdings, Inc. (IQV) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 35.27% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

The debt-to-equity ratio of 255.43% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

With a PEG ratio of 0.72, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 11.82x is meaningfully below the trailing 20.87x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 35.27% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy IQVIA Holdings, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.